Abstract:Abstract Disclosure: A.F. Turcu: None. Z. Salman: None. S.M. Konzen: None. L. Zhang: None. H. Liu: None. L. Zhao: None. T. Suzer Gurtekin: None. M. Papaleontiou: None. Background: Primary aldosteronism (PA) is the most common cause of endocrine hypertension, affecting up to 25% of patients with treatment-resistant hypertension. PA contributes to cardiovascular and renal morbidity and mortality, via mechanisms additive to hypertension. Early detection and targeted therapy of PA mitigate the risk of such complications. Despite this, only a minute fraction of patients at risk are ever screened for PA. Objective: To ascertain triggers and barriers for PA screening across US practices. Methods: Physicians treating hypertension, including internists, family practitioners, cardiologists, nephrologists, and endocrinologists, were randomly selected from active members of the American Medical Association. Physicians were surveyed on their practice of PA screening. Multivariable logistic regression was performed to determine factors associated with PA screening. Results: Of 633 response-eligible physicians, 425 (67%) completed the survey, including 32.4% family practitioners, 26.9% internists, 13.2% cardiologists, 12.2% endocrinologists, and 11.8% Nephrologists. Of the respondents, 230 (55.2%) were men; 63% identified as White, 24% Asian, and 6% Black. Most participants reported that resistant hypertension (84.5%), and hypertension and spontaneous hypokalemia (81.4%) prompt them to screen for PA. Conversely, a minority reported diuretic-induced hypokalemia (26%), obstructive sleep apnea (10%), or atrial fibrillation (6.2%) as triggers for PA screening. Compared with internists, endocrinologists and nephrologists were more likely, and family practitioners were less likely to screen for PA in patients with hypertension and hypokalemia, early-onset hypertension, or adrenal nodules. Barriers to PA screening included clinic visit time constraints (37.4%), poor ancillary support (28.1%), testing logistic concerns (26.2%), ability to control hypertension with medications (20.5%), and belief that PA is rare (20.2%). Female physicians and family practitioners were more likely to report not being familiar with results’ interpretation and next steps, and not having time to keep abreast with expert guidelines; private practitioners were most likely to report reimbursement concerns. Conclusions: Heterogeneity in screening for PA exists among physicians at the frontline of hypertension care. Increasing awareness and developing tools to facilitate PA screening are crucial for the recognition and adequate care of millions of patients with hypertension. Presentation: Friday, June 16, 2023

Challenges in screening tests of primary aldosteronism

Hyperaldosteronism: Screening and Diagnostic Tests

The role of confirmatory tests in the diagnosis of primary aldosteronism

Performance of aldosterone-to-renin ratio before washout of antihypertensive drugs in screening of primary aldosteronism

Case Series: Primary Aldosteronism Diagnosed Despite Normal Screening Investigations: A Report of Three Cases

Diagnostic Accuracy of Aldosterone and Renin Measurement by Chemiluminescence for Screening of Patients with Primary Aldosteronism

Who needs to be screened for primary aldosteronism?

Stroke Risks in Primary Aldosteronism with Different Treatments: A Systematic Review and Meta-Analysis

Clinical significance of LC-MS/MS aldosterone in screening for primary aldosteronism

Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups

Primary Aldosteronism: Who Should be Screened?

Captopril challenge test: an underutilized test in the diagnosis of primary aldosteronism

EVALUATION AND COMPARISON OF DIAGNOSTIC EFFICACY OF INDICATORS TO SCREENING FOR PRIMARY ALDOSTERONISM BEFORE ENDOCRINE PATHWAY

Optimizing the aldosterone-to-renin ratio cut-off for screening primary aldosteronism based on cardiovascular risk: a collaborative study

Screening parameters for diagnosing primary aldosteronism in patients with moderate to severe obstructive sleep apnea hypopnea syndrome and resistant hypertension

The Association Between Egfr and the Aldosterone-to-Renin Ratio and Its Effect on Screening for Primary Aldosteronism.

Screening for primary aldosteronism in primary care: a scoping review

FRI122 Determinants of Primary Aldosteronism Screening in the US: A Nationwide Physician Survey Study

Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation

Taiwan mini-frontier of primary aldosteronism: Updating detection and diagnosis

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism